Vistagen Announces Phase 3 Program For Social Anxiety Disorder With Fasedienol; First Enrollment In U.S. Study For Efficacy, Safety, Tolerability During Public Speaking Challenge

BenzingaJan 10 08:37 ET

Express News | Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

ReutersJan 10 08:30 ET

VistaGen Therapeutics Advances Neurocircuitry Treatments

TipRanksDec 6, 2024 17:18 ET

Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsNov 21, 2024 08:31 ET · Ratings

Vistagen to Present at the Stifel 2024 Healthcare Conference

BusinesswireNov 14, 2024 08:30 ET

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript Summary

moomoo AINov 10, 2024 08:04 ET · Conference Call